FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...

Evoke Pharma's stock soared 168% on Wednesday after the company announced it had received a new U.S. patent that could extend ...

The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® ...

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, is poised as a game-changer for emergency allergies, driving growth.

A new study shows that oxytocin nasal spray helps mothers with postpartum depression interact more positively with their babies.

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

New Opportunities will be offering a free “Be Prepared” presentation to assist in identifying and how to respond to an opioid overdose. On July 18 at the Audubon Rec Center Community Room, New Opportu ...